Bristol-Myers Squibb Opens Expanded Biologics Facility

DEVENS, Mass.–(BUSINESS WIRE)– Bristol-Myers
Squibb (NYSE:BMY) today celebrated the completion of a major
expansion at its Devens, MA biologics facility designed to accelerate
development of the company’s growing portfolio of biologics medicines.

This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160517006302/en/

Bristol-Myers Squibb has completed a major expansion at its Devens, MA, biologics facility designed to accelerate development of the company’s growing portfolio of biologics medicines. The $280 million project adds two new buildings to the 89-acre Devens campus: a Biologics Development Building for designing processes for the early production of investigational medicines, and a Clinical Manufacturing Building where investigational medicines will be produced to support clinical trials. Both are new capabilities for Devens, a site that had previously focused solely on large-scale, commercial biologics manufacturing. (Photo: Business Wire)

The $280 million project adds two new buildings to the 89-acre Devens
campus: a Biologics Development Building for designing processes for the
early production of investigational medicines, and a Clinical
Manufacturing Building where investigational medicines will be produced
to support clinical trials. Both are new capabilities for Devens, a site
that had previously focused solely on large-scale, bulk biologics
manufacturing.

“Biologics are increasingly important in the treatment of serious
diseases and a rapidly growing part of our company’s pipeline of
potential new therapies,” said Lou
Schmukler, president, Global Manufacturing & Supply. “Bringing
together biologics development and clinical and commercial manufacturing
on one campus will help accelerate the development of these innovative
medicines for patients worldwide.”

The expansion increases the site’s workforce, with approximately 200 new
jobs having been added at the project’s initial completion rising to
approximately 350 jobs over time. The two new buildings also add
approximately 200,000 square feet to a site now comprised of eight major
buildings in a 600,000 square-foot complex. Furthermore, the buildings
add to the major investment the company has made at Devens, a former
military base. When combined with the company’s initial $750 million
investment to build the facility, the expansion project brings the
company’s total investment at the site to more than $1 billion.

“This project represents a significant expansion in the site’s size and
mission,” said Greg Guyer, senior vice president, Biologics Development
and Operations. “It creates one of the world’s premier integrated
biologics facilities, a biologics center of excellence for the company,
for the Commonwealth of Massachusetts, and for patients.”

The new buildings are also representative of a broader company
initiative to incorporate more efficient design and workspaces that
enable collaboration, creativity and innovation in all its facilities.
Pedestrian bridges connect the different buildings at Devens, while
interior design elements encourage interaction among the teams working
in the closely linked scientific disciplines of biologics process
development, clinical manufacturing and commercial manufacturing.

“These dynamic new buildings, and our site as a whole, are designed to
advance the important work that our employees are doing to develop and
deliver innovative medicines for patients with serious diseases,” said
Luis Maranga, the site’s general manager.

The buildings also continue our company’s commitment to sustainability
in its buildings and operations. The Biologics Development Building has
received Leadership in Energy and Environmental Design (LEED^®)
Silver certification for energy and environmental design, and the
Clinical Manufacturing Building is also targeted for LEED Silver
certification. Sustainable features in the new buildings include an
abundance of natural light, a green roof, high efficiency lighting and
water systems, water-efficient landscaping, and wood products from
sustainable sources. The site’s original lab and office building had
previously received LEED Gold certification, while the manufacturing
building received Silver.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information about
Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter,
YouTube
and Facebook.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160517006302/en/